PM00104 (Zalypsis®): a marine derived alkylating agent
Bradley J Petek1, Robin L Jones2
1University of Washington School of Medicine, 1959 NE Pacific St, Seattle, WA 98195, USA. bpetek@uw.edu.
Molecules (Basel, Switzerland)
|August 26, 2014
Summary
PM00104, a synthetic DNA-binding alkaloid, shows promise as a chemotherapy agent for solid tumors and blood cancers. Clinical trials are reviewing its efficacy in cancer treatment.
Area of Science:
- Pharmacology
- Oncology
- Medicinal Chemistry
Background:
- PM00104 is a synthetic tetrahydroisoquinolone alkaloid with structural similarities to marine natural products.
- It is being investigated as a potential chemotherapeutic agent for various cancers.
Purpose of the Study:
- To review current clinical trials of PM00104.
- To evaluate the efficacy of PM00104 as a future cancer therapeutic.
Main Methods:
- Review of Phase II clinical trial data.
- Assessment of PM00104's mechanism of action (DNA binding, cell cycle inhibition, transcription inhibition, DNA breaks).
Main Results:
- PM00104 demonstrates DNA binding properties.
- The compound inhibits cell cycle progression and transcription, leading to DNA damage.
- Clinical trial data is being appraised for efficacy.
Conclusions:
- PM00104 exhibits a promising mechanism of action for cancer treatment.
- Further evaluation of clinical trial results is necessary to determine its future role in oncology.
